TD Waterhouse Canada Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 68.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 153,802 shares of the biopharmaceutical company’s stock after selling 328,399 shares during the period. TD Waterhouse Canada Inc.’s holdings in Gilead Sciences were worth $22,698,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp raised its stake in Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares during the last quarter. Amundi lifted its position in Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new stake in Gilead Sciences during the 2nd quarter worth about $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in Gilead Sciences during the 2nd quarter worth about $918,387,000. 83.67% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the completion of the sale, the chief executive officer owned 577,133 shares in the company, valued at $85,785,049.12. The trade was a 2.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on GILD shares. Bank of America reiterated a “buy” rating and set a $164.00 price target on shares of Gilead Sciences in a research note on Monday, October 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Thursday, October 8th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Barclays decreased their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Finally, Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.33.
Read Our Latest Research Report on GILD
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Vir oncology collaboration expands Gilead’s pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
- Positive Sentiment: Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies—including Gilead—have traded near record highs. This rotation may be supporting demand for GILD because of the sector’s defensive characteristics and potential earnings support. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
- Neutral Sentiment: Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company’s prospects. Gilead Sciences rises higher than market: Key facts
- Negative Sentiment: Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Gilead CFO Form 4 filing
Gilead Sciences Stock Down 0.7%
NASDAQ:GILD opened at $156.19 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company’s fifty day moving average price is $147.19 and its 200-day moving average price is $137.29. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $160.51. The firm has a market capitalization of $193.67 billion, a P/E ratio of -58.50 and a beta of 0.31.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.01 earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.47 EPS for the current year.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
